The approval of Novartis’ breakthrough therapy for a deadly form of leukemia has opened the door to a new class of treatments even as its price tag reignited a debate.
AstraZeneca shares have plunged by the most ever after the UK drugmaker suffered a blow to its next-generation cancer therapy in a major setback.
AstraZeneca has a track record of bringing drugs back from the dead. But in the case of the latest setback on a key cancer study, the odds are stacked against the company.
Aspen has lost its appeal against an Italian Competition Authority ruling, meaning it must now pay a €5.2m fine, the pharmaceutical company has announced.
Cape TownHire ResolveR1 300 000.00 - R1 600 000.00 Per Year
Western CapePersona Staff
Cape Town Northern SuburbsMonotecR6 000.00 - R15 000.00 Per Month
R 6 100 000
R 5 525 000
R 5 300 000
We subscribe to the Press Code.
You choose what you want
News24 on Android
Get the latest from News24 on your Android device.
Terms and Conditions
24.com Terms and Conditions - Updated April 2012
Creating your profile will enable you to submit photos and stories to get published on News24.
This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.